L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 12, 2013, Pages 4804-4809

  Nasca, Carla ^a   Xenos, Dionysios ^a   Barone, Ylenia ^b   Caruso, Alessandra ^a   Scaccianoce, Sergio ^a   Matrisciano, Francesco ^a   Battaglia, Giuseppe ^c   Mathé, Aleksander A ^d   Pittaluga, Anna ^e   Lionetto, Luana ^f   Simmaco, Maurizio ^f   Nicoletti, Ferdinando ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS NEUROMED   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GENOA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BDNF; Chromatin; Glutamatergic neurotransmission; Histone acetylation; MDD

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; LEVACECARNINE; METABOTROPIC RECEPTOR 2; SUCROSE; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EPIGENETICS; FORCED SWIMMING TEST; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACETYLATION; ACETYLCARNITINE; AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; CLOMIPRAMINE; EPIGENESIS, GENETIC; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; HISTONE DEACETYLASES; HISTONES; HUMANS; MALE; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NF-KAPPA B; NOOTROPIC AGENTS; PREFRONTAL CORTEX; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; TIME FACTORS; XANTHENES;

EID: 84875278408     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216100110     Document Type: Article

References (48)

1. Perroud N (2011) Suicidal ideation during antidepressant treatment: Do genetic predictors exist? CNS Drugs 25:459-471.
2. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63:530-538.
3. Mill J, Petronis A (2007) Molecular studies of major depressive disorder: The epigenetic perspective. Mol Psychiatry 12:799-814.
4. Autry AE, Monteggia LM (2009) Epigenetics in suicide and depression. Biol Psychiatry 66:812-813.
5. Tsankova NM, et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519-525.
6. Weaver IC, et al. (2004) Epigenetic programming by maternal behavior. Nat Neurosci 7:847-854.
7. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969.
8. Galli M, et al. (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 89:185-190.
9. Youle M (2007) Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 21(Suppl 1):25-30.
10. Chiechio S, et al. (2009) Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 75: 1014-1020.
11. Chiechio S, et al. (2006) Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: A possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2:20.
12. Chiechio S, et al. (2010) Transcriptional regulation of type-2 metabotropic glutamate receptors: An epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 31:153-160.
13. Nicoletti F, et al. (2011) Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology 60:1017-1041.
14. Matrisciano F, et al. (2007) Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: A new strategy to shorten the latency of antidepressant medication? Mol Psychiatry 12:704-706.
15. Matrisciano F, et al. (2008) Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 55:525-531.
16. Neugebauer V, Galhardo V, Maione S, Mackey SC (2009) Forebrain pain mechanisms. Brain Res Brain Res Rev 60:226-242.
17. Robinson MJ, et al. (2009) Depression and pain. Front Biosci 14:5031-5051.
18. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894-902.
19. Krishnan V, Nestler EJ (2010) Linking molecules to mood: New insight into the biology of depression. Am J Psychiatry 167:1305-1320.
20. Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:1383-1385.
21. Covington HE, 3rd, et al. (2009) Antidepressant actions of histone deacetylase inhibitors. J Neurosci 29:11451-11460.
22. Morishima Y, et al. (2005) Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc Natl Acad Sci USA 102:4170-4175.
23. De Bodinat C, et al. (2010) Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev Drug Discov 9:628-642.
24. McEwen BS, et al. (2010) The neurobiological properties of tianeptine (Stablon): From monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 15:237-249.
25. Jiménez-Vasquez PA, et al. (2007) Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur Neuropsychopharmacol 17(4):298-308.
26. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS (1993) Chronic mild stressinduced anhedonia: Greater effect in a genetic rat model of depression. Physiol Behav 54:1215-1220.
27. Fritz EB, McEwen BS (1959) Effect of carnitine on fatty-acid oxidation by muscle. Science 128:334.
28. Costell M, Miguez MP, O'Connor JE, Grisolin SC (1987) Effect of hyperammonemia on the levels of carnitine in mice. Neurology 37:804-808.
29. Shimizu E, et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75.
30. Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 64:527-532.
31. Bjørnebekk A, Mathé AA, Gruber SH, Brené S (2008) Housing conditions modulate escitalopram effects on antidepressive-like behavior and brain neurochemistry. Int J Neuropsychopharmacol 11:1135-1147.
32. Elfving B, et al. (2010) Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 13:563-572.
33. Popoli M, Yan Z, McEwen BS, Sanacora G (2011) The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13:22-37.
34. Lowy MT, Wittenberg L, Yamamoto BK (1995) Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 65: 268-274.
35. Moghaddam B (2002) Stress activation of glutamate neurotransmission in the prefrontal cortex: Implications for dopamine-associated psychiatric disorders. Biol Psychiatry 51:775-787.
36. Bagley J, Moghaddam B (1997) Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: Effects of pretreatment with saline or diazepam. Neuroscience 77:65-73.
37. Raiteri L, Raiteri M (2000) Synaptosomes still viable after 25 years of superfusion. Neurochem Res 25:1265-1274.
38. Chen LF, Fischle W, Verdin E, Greene WC (2001) Duration of nuclear NF-kB action regulated by reversible acetylation. Science 293:1653-1657.
39. Kurita M, et al. (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15:1245-1254.
40. Chaki S, et al. (2013) mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology, 66:40-52.
41. Kovacevic T, et al. (2012) Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. Brain Res Bull 87:406-412.
42. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476.
43. Yasuhara A, et al. (2006) Prodrugs of 3-(3, 4-dichlorobenzyloxy)-2-amino- 6- fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 14:4193-4207.
44. Yoshimizu T, Shimazaki T, Ito A, Chaki S (2006) An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186:587-593.
45. Fell MJ, et al. (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4- (isobutyryl) phenoxy) methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336:165-177.
46. Tsunoka T, et al. (2009) Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol 33:875-879.
47. Zanardi R, Smeraldi E (2006) A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 16:281-287.
48. Garzya G, et al. (1990) Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 16:101-106.